Sentinel Lymph Node Biopsy for Patients With cN1 HR+/HER2− Breast Cancer and Palpable Adenopathy
JAMA Surgery · 01.07.2026 · 161 (7) · 662
DOI: 10.1001/jamasurg.2026.1268 ↗Kurz gefasst
Klinische Studie in der Zeitschrift JAMA Surgery, erschienen am 01.07.2026. Verfasst von Anita Mamtani und 26 weiteren Autor:innen. Beteiligte Einrichtung: Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Breast Neoplasms, Sentinel Lymph Node Biopsy, Lymphadenopathy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Randomized trials established the safety of omitting axillary lymph node dissection (ALND) among patients with clinically node-negative breast cancer and less than 3 positive sentinel lymph nodes (+SLNs) having upfront surgery and adjuvant radiation. Patients with palpable mobile level I/II axillary adenopathy (cN1) were not eligible for these studies. Presently, more than 80% of patients with HR+/HER2− cN1 disease undergo ALND either at upfront surgery or after neoadjuvant therapy, despite evidence that 50% to 60% will have only 1 or 2 positive nodes.
Objective
To determine upfront sentinel lymph node biopsy (SLNB) feasibility and evaluate ALND rate among patients with HR+/HER2− cN1 breast cancer selected with axillary ultrasound (AUS). Design, Setting, and Participants This nonrandomized clinical trial involved patients with cTx/cT1-2 cN1 HR+/HER2− breast cancer with 3 or fewer morphologically abnormal nodes on AUS at 4 centers. The trial began on April 20, 2021, and the database for this report was frozen on September 26, 2024.
Interventions
Patients underwent upfront lumpectomy/mastectomy and SLNB, with single/dual-tracer mapping. ALND was indicated for 3 or more positive SLNs. Main Outcomes and Measures The primary outcome was ALND rate. Secondary outcomes were frequency of palpable nodes being radioactive/blue and locoregional recurrence.
Results
Among 78 enrolled patients, the median (IQR) age was 58 (49.0-66.5) years. Most tumors were cT1 (37 [47%]) or cT2 (40 [51%]), 56 patients (72%) had ductal histology, and 59 tumors (76%) were moderately differentiated. On AUS, 39 patients (50%) had 1 abnormal-appearing node, 33 (42%) had 2, and 6 (8%) had 3. Median (IQR) pathologic tumor size was 2.3 (1.6-3.3) cm, 50 patients (64%) had lymphovascular invasion, and 54 (69%) had extracapsular extension. SLNB was performed with dual tracer in 68 (87%), and 3 or more SLNs were retrieved in 75 (96%). The palpable diseased nodes were blue and/or radioactive in 107 of 161 instances (66.5%). Overall, 24 patients (31%) had 1 +SLN, 30 patients (38%) had 2 +SLNs, and 24 patients (31%) had 3 or more +SLNs. SLNB alone was performed in 59 patients (76%), while 19 (24%) had ALND; indicated ALND was deferred in 5 cases. Among those with 12 months or more follow-up (n = 68; median, 25 months), there have been no isolated axillary or locoregional recurrences. Conclusions and Relevance This study found that SLNB is feasible among patients with cN1 HR+/HER2− disease and that resection of palpable nodes is necessary to minimize false-negative rates. This approach affords the opportunity to omit ALND and minimize morbidity among patients with cN1 cancer and limited nodal burden. Trial Registration ClinicalTrials.gov Identifier: NCT04854005
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Surgery, University of Michigan, Ann Arbor.
- Department of Surgery, Hartford HealthCare, Hartford, Connecticut.
- Lehigh Valley Topper Cancer Institute, Lehigh Valley Health Network, Lehigh Valley, Pennsylvania.
- Department of Surgery, NYU Grossman School of Medicine, NYU Langone Health, New York, New York.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Zitieren
APA
Mamtani, A., Pilewskie, M., Wilson, N., Chung Whang, H., Barrio, A. V., Bassin, L., Capko, D., Choi, D. X., Cody, H. S., Downs-Canner, S., El-Tamer, M., Gemignani, M. L., Heerdt, A. S., Kirstein, L., Lee, M. K., Mango, V. L., Montagna, G., Moo, T. A., Oxenberg, J., …, & Morrow, M. (2026). Sentinel Lymph Node Biopsy for Patients With cN1 HR+/HER2− Breast Cancer and Palpable Adenopathy. JAMA Surgery, 161(7), 662. https://doi.org/10.1001/jamasurg.2026.1268
Vancouver
Mamtani A, Pilewskie M, Wilson N, Chung Whang H, Barrio AV, Bassin L, et al. Sentinel Lymph Node Biopsy for Patients With cN1 HR+/HER2− Breast Cancer and Palpable Adenopathy. JAMA Surgery. 2026;161(7):662. doi:10.1001/jamasurg.2026.1268
BibTeX
@article{Mamtani2026,
author = {Mamtani, Anita and Pilewskie, Melissa and Wilson, Niamey and Chung Whang, Heiwon and Barrio, Andrea V and Bassin, Leah and Capko, Deborah and Choi, Daniel X and Cody, Hiram S and Downs-Canner, Stephanie and El-Tamer, Mahmoud and Gemignani, Mary L and Heerdt, Alexandra S and Kirstein, Laurie and Lee, Minna K and Mango, Victoria L and Montagna, Giacomo and Moo, Tracy-Ann and Oxenberg, Jacqueline and Plitas, George and Sabel, Michael and Sacchini, Virgilio and Sclafani, Lisa and Sevilimedu, Varadan and Tadros, Audree B and Van Zee, Kimberly J and Morrow, Monica},
title = {Sentinel Lymph Node Biopsy for Patients With cN1 HR+/HER2− Breast Cancer and Palpable Adenopathy},
journal = {JAMA Surgery},
year = {2026},
volume = {161},
number = {7},
pages = {662},
doi = {10.1001/jamasurg.2026.1268}
}
EUVIMED